Sigyn Therapeutics Launches Initiative to Evaluate CardioDialysis for CTE in Former NFL Players
summarizeSummary
Sigyn Therapeutics has announced a new initiative to evaluate emerging medical technologies, including its proprietary CardioDialysis device, for the diagnosis, monitoring, and treatment of chronic traumatic encephalopathy (CTE) in former NFL players. The company's CardioDialysis technology aims to reduce inflammatory and pathogenic molecules, which have been identified as a principal driver of CTE progression. This move represents a strategic expansion into a significant unmet medical need, potentially broadening the application of their core technology beyond its current focus. For a micro-cap company, this initiative could be a material step towards validating and commercializing their device in a new, high-profile therapeutic area. Investors will be watching for updates on the feasibility studies and any subsequent clinical development plans.
At the time of this announcement, SIGY was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $48.2K. The 52-week trading range was $0.01 to $21.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.